PD0325901
Modify Date: 2024-01-02 21:43:01
PD0325901 structure
|
Common Name | PD0325901 | ||
|---|---|---|---|---|
| CAS Number | 391210-10-9 | Molecular Weight | 482.193 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C16H14F3IN2O4 | Melting Point | 112-114ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS06, GHS08, GHS09 |
Signal Word | Danger | |
Use of PD0325901PD0325901 is a selective and cell permeable MEK inhibitor with an IC50 of 0.33 nM. |
| Name | (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | PD0325901 is a selective and cell permeable MEK inhibitor with an IC50 of 0.33 nM. |
|---|---|
| Related Catalog | |
| Target |
MEK1:0.33 nM (IC50) Autophagy |
| In Vitro | PF0325901 shows higher permeability, and should be able to achieve higher systemic exposures than CI-1040[1]. PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GC50 of 11 nM and 6.3 nM, respectively. PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines[2]. |
| In Vivo | PD0325901 (25 mg/kg, p.o.) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. The dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. PD0325901 (20-25 mg/kg/day, p.o.) treatment in mice, shows no tumor growth inoculated with PTC cells bearing a BRAF mutation. For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement[2]. |
| Kinase Assay | Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves. |
| Cell Assay | PTC cells (1×104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37°C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GC50 or every day for cell growth curves. The cells are incubated at 37°C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GC50, cell growth is calculated as 100×(T−T0)/(C−T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only. |
| Animal Admin | Mice (10-14 per group) are anesthetized s.c. with a cocktail (100 μL/10 g body weight of 10 mg/mL keta-mine and 1 mg/mL xylazine). K2 and TPC-1 cells stably infected with a retrovirus expressing luciferase (5×105 cells in 5 μL RPMI1640 medium) are inoculated into the thyroid gland, and the mice are monitored weekly for tumor growth by Xenogen using Living Image 3.0 software. One week after inoculation, PD0325901 is dissolved in 80 mM citric buffer (pH 7) by sonication and given to mice daily by oral gavage (20-25 mg/kg) for 3 weeks (5 consecutive days/week). Mice are sacrificed only due to tumor burden or loss of 20% of body weight. Tumor sizes are measured with calipers and tumor volume (V) is calculated by the formula (V=length×width×depth). Control mice are given 80 mM citric buffer (pH 7) alone. All in vivo experiments are done at least twice. |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Melting Point | 112-114ºC |
| Molecular Formula | C16H14F3IN2O4 |
| Molecular Weight | 482.193 |
| Exact Mass | 481.995026 |
| PSA | 90.82000 |
| LogP | 6.16 |
| Appearance of Characters | white to off-white |
| Index of Refraction | 1.645 |
| Storage condition | Store at -20°C |
| Water Solubility | DMSO: soluble20mg/mL, clear |
| Symbol |
GHS06, GHS08, GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H373-H410 |
| Precautionary Statements | P273-P301 + P310 + P330-P391-P501 |
| Hazard Codes | T,N |
| Risk Phrases | 25-48-50 |
| Safety Phrases | 22-36/37/39-61 |
| RIDADR | UN 2811 6.1 / PGIII |
|
~%
PD0325901 CAS#:391210-10-9 |
| Literature: US2005/85550 A1, ; Page/Page column 8 ; |
|
~71%
PD0325901 CAS#:391210-10-9 |
| Literature: US2005/85550 A1, ; Page/Page column 8 ; |
![N-{[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide structure](https://image.chemsrc.com/caspic/398/391212-52-5.png)
| Precursor 3 | |
|---|---|
| DownStream 0 | |
|
Inhibition of mTORC1 Enhances the Translation of Chikungunya Proteins via the Activation of the MnK/eIF4E Pathway.
PLoS Pathog. 11 , e1005091, (2015) Chikungunya virus (CHIKV), the causative agent of a major epidemic spanning five continents, is a positive stranded mRNA virus that replicates using the cell's cap-dependent translation machinery. Des... |
|
|
cAMP and EPAC Signaling Functionally Replace OCT4 During Induced Pluripotent Stem Cell Reprogramming.
Mol. Ther. 23 , 952-63, (2015) The advent of induced pluripotent stem cells--generated via the ectopic overexpression of reprogramming factors such as OCT4, SOX2, KLF4, and C-MYC (OSKM) in a differentiated cell type--has enabled gr... |
|
|
Mesenchymal stem cell-derived inflammatory fibroblasts promote monocyte transition into myeloid fibroblasts via an IL-6-dependent mechanism in the aging mouse heart.
FASEB J. 29 , 3160-70, (2015) Fibrosis in the old mouse heart arises partly as a result of aberrant mesenchymal fibroblast activation. We have previously shown that endogenous mesenchymal stem cells (MSCs) in the aged heart are ma... |
| N-[(2R)-2,3-dihydroxyproposy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide |
| Benzamide, N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- |
| (R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide |
| PD 0325901 |
| N-[(R)-2,3 -Dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide |
| N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide |
| N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide |
| (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide |
| PD0325901 |